Figure 4
From: Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis
Effect of TAT-BID on viability of PC3 cells treated with TRAIL or CPT. A. Viability of cells treated with 30 μg/ml of the wild type TAT-BID (light bars) or TAT-BIDT59AS76A (dark bars) and 100 ng/ml of TRAIL for 24 h. B. Viability of cells treated with 30 μg/ml of TAT-BIDD60E and 200 ng/ml of TRAIL for 24 h. There is no statistically significant difference between viability of TRAIL- and TAT-BIDD60E-treated cells. C. Dose-dependent TAT-BIDD60E uptake by PC3 cells measured after 120 min. D. Viability of cells treated with 30 μg/ml of TAT-BID and 30 nM of CPT. Viability of cells treated with TAT-BID for 24 h was measured by MTT test. The average of cells viability (±SD) was shown. A and D. Viability of control (control) and TRAIL- or CPT-treated cells (TRAIL or CPT, respectively) are valid in each case for both TAT-BID and TAT-BIDT59AS76A.